Search

everythinglearnresearchcommunity

for

Search:↓

Pyrilutamide, a new hair loss product with the potential to be more effective than RU58841 and safer than CB, but expensive.

PP405 is expected to be more expensive than finasteride and minoxidil initially due to patent protection, but not as costly as life-saving medications like Ozempic. The price may decrease after the patent expires, but initially, it might be around $100 per month, making it potentially unaffordable for many.

A 24-year-old shares their positive 4-month progress using 0.5 mg oral finasteride and 5% topical minoxidil for hair loss, reporting no significant side effects. Other users discuss similar experiences and regimens, with some expressing concerns about potential side effects.

The conversation is about the quality of RU58841 powder from Shaanxi Laon Biotech. The user is inquiring if anyone has experience with this product.

User shared a 4-month progress update on using minoxidil and 1.5 months on finasteride for hair loss. Reactions were mixed, with some expressing disbelief and others feeling inspired to start treatment.

The user shared progress pictures showing improvement in hair loss after 4 months of using Minoxidil and plans to start Finasteride. They received advice to stay consistent and consider oral Minoxidil.

Scube3, a potential hair loss treatment, is unlikely to be released because it was given to a startup company, Amplifica, which may go bankrupt and fail to bring the treatment to market. Amplifica is prioritizing other treatments over Scube3, which could lead to financial loss and the end of Scube3's development.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

The user reports using Minoxidil, finasteride, microneedling, ketoconazole shampoo, rosemary oil, biotin, and multivitamins for hair loss treatment. They've noticed a significant reduction in hair shedding and an improvement in hair texture.

PP405 shows promising results for hair density improvement, potentially outperforming Minoxidil in a shorter time. However, its public release is expected around 2029/2030, and its cost and availability remain uncertain.

Verteporfin treatment shows promise for hair regeneration and reducing scar tissue in hair transplants. Some users plan to try verteporfin with hair transplants, and it may also be combined with PRP in future experiments.

Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.

PP405 is progressing rapidly through trials, with mixed opinions on its potential effectiveness. Current treatments like minoxidil and finasteride are still widely discussed, with some users reporting positive results from new formulations.

User shows hair loss progress from NW4 to NW2.5 in 2.5 months using RU 8.5-9% daily and topical Dut .1% + RU 5% weekly. Discussion includes managing tension in African American hair and representation of different hair types.

The conversation discusses the use of Verteporfin in treating hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

A 44-year-old user experienced hair regrowth using a topical spray combining 0.3% finasteride and 7% minoxidil after switching from oral finasteride due to side effects. The user reported noticeable improvements in hair thickness after four months without any side effects from the topical treatment.

The conversation is about whether the phase 2 results for pyrilutamide, a potential hair loss treatment, were presented at a dermatology convention and inquiries about the completion of phase 3 trials. Specific treatments mentioned include pyrilutamide.

RU58841 solution developed crystals after refrigeration. Letting it reach room temperature and shaking can dissolve the crystals.

The user is looking for a PG-free solvent in the UK or EU to make their own pyrilutamide solution for hair loss and is currently using finasteride, considering minoxidil. They hope pyrilutamide will help stabilize their hair loss.

People are discussing the potential of a new hair loss treatment, pp405, and its approval timeline, comparing it to existing treatments like Minoxidil and finasteride. There is skepticism about its effectiveness and concerns about the time it will take for approval and availability, especially in Europe.

The user's progress with their hair loss treatment of topical minoxidil and finasteride solution, as well as scalp massage; other users commenting on the results being impressive for someone of Asian background.

A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.

The user is using oral minoxidil and finasteride for hair loss and plans to add topical minoxidil and a dermaroller. They also use ketoconazole shampoo to support hair regrowth.

The conversation discusses using verteporfin for hair regrowth and minimizing scarring after hair transplants. Some individuals plan to self-administer verteporfin, potentially in combination with microneedling, as an alternative to hair transplants.

The user experienced some hair regrowth after 4 months of inconsistent use of topical finasteride and minoxidil, with no noticeable side effects. Others suggest trying oral finasteride and minoxidil for better consistency.

User shared 4-month progress on hair loss treatment using 0.25mg finasteride daily and topical minoxidil daily, noting cognitive decline possibly linked to finasteride. Users discussed side effects, alternative treatments, and shared similar experiences.

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

User suggests a DIY zix formula for hair loss treatment and shares personal success with it. Another user disagrees, calling zix a "snake oil potion" and advises finding a real treatment instead.

Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.

The conversation discusses hair regrowth results after using finasteride, minoxidil, and dermarolling for four months. Users inquire about dosages and when results were first noticed.